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http://dx.doi.org/10.1016/j.ccr.2012.09.009SUMMARYHow inflammation causes cancer is unclear. Interleukin-15 (IL-15) is a pro-inflammatory cytokine elevated in
human large granular lymphocyte (LGL) leukemia. Mice overexpressing IL-15 develop LGL leukemia. Here,
we show that prolonged in vitro exposure of wild-type (WT) LGL to IL-15 results in Myc-mediated upregula-
tion of aurora kinases, centrosome aberrancies, and aneuploidy. Simultaneously, IL-15 represses miR-29b
via induction of Myc/NF-kBp65/Hdac-1, resulting in Dnmt3b overexpression and DNA hypermethylation.
All this is validated in human LGL leukemia. Adoptive transfer of WT LGL cultured with IL-15 led to malignant
transformation in vivo. Drug targeting that reversesmiR-29b repression cures otherwise fatal LGL leukemia.
We show how excessive IL-15 initiates cancer and demonstrate effective drug targeting for potential therapy
of human LGL leukemia.INTRODUCTION
There are strong epidemiologic data to support the notion that
chronic inflammation can increase the risk for malignant trans-
formation of otherwise normal host cells (Ames et al., 1995).
Deregulated cytokine production in the context of persistent
infections can stimulate cells expressing cognate cytokine re-
ceptors to alter cell growth, cell differentiation, and cell survival,Significance
Our best opportunity for curing cancer will come from a compl
associated with the progression of cancer but few if any studie
show how an excess of a single pro-inflammatory cytokine, IL-
tion, leading to an aggressive acute leukemia of large granula
show how drug targeting of the aberrant pathways induced
the molecular mechanisms involved in the genesis of cancer
such cancers.
Canputting a cell at increased risk for malignant transformation when
exposed to DNA damaging agents (Dranoff, 2004). For example,
overexpression of macrophage-migration inhibitory factor in
the setting of chronic inflammation can lead to the functional
inactivation of the tumor suppressor gene p53 (Hudson et al.,
1999), and overexpression of interleukin-1 (IL-1) is associated
with an increased risk of developing gastric cancer (El-Omar
et al., 2000). While the alteration of cytokine gene expressionete understanding of its causes. Inflammation has long been
s have shown how inflammation can initiate cancer. Here, we
15, causes chromosomal instability and DNA hypermethyla-
r lymphocytes, a rare yet uniformly fatal form of cancer. We
by excessive IL-15 can cure this cancer. Thus, elucidating
that results from chronic inflammation has merit for curing
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Figure 1. Chronic Exposure to IL-15 Initiates Robust Expansion and
Chromosomal Instability in WT LGL
(A) Fold changes in expression of IL-15mRNA in human LGL leukemia samples
from three patients (Pt), normalized to 18S mRNA and then quantified relative
to values of IL-15measured in normal donor cells that were enriched for either
CD56+ or CD8+ (n = 4 each) and then arbitrarily set at 1.
(B) Schema for the generation of in vitro robust expansion of WT LGL during
culture in IL-15 and adoptive transfer followed by malignant transformation
in vivo in the absence of exogenous IL-15. Scale bars, 10 mm.
(C) WT splenic NK1.1+ cells were sorted and incubated in triplicate with
100 ng/ml rhIL-15. Cell growth was quantified as absolute number of cells
(mean ± SEM) using enumeration in trypan blue exclusion dye. Wright-Giemsa
stain of the in vitro cultured cells. Scale bars, 10 mm.
(D) WT LGL were analyzed for their immuno-phenotype by FACS after
6 months of in vitro culture with IL-15.
(E) Karyotype analysis was performed on metaphase spreads from WT LGL
cultured in IL-15 for approximately 6 months, demonstrating marked aneu-
ploidy. Composite karyotype of the in vitro transformed WT LGL cells was:
76-79 < 4n > ,XXX,-X,-1,-3,del(4)(A1A2),-4,-5,+8,+8,+12,del(12)(A1.2B),-14,
der(15)t(5;15)(B1;F2),-17,+19,+mar[cp7]/76 79,idem,+6[cp10]/76-79,idem,+
19[cp3].
(F) ICR-SCID mice were intravenously injected with 13 107 WT LGL following
approximately 8 months of in vitro culture with IL-15. Splenomegaly
(compared to WT control as shown) and the presence of neoplastic LGL, both
at the feathered edge of peripheral blood smear and on the spleen cytospin
preparation, are shown. Scale bars, 10 mm. A representative FISH image
illustrating gain of several copies chromosome 15 (red, chromosome 15 probe;
blue, DAPI counter-stain) as seen in WT LGL cultured in vitro for months in
IL-15 (E) is also shown. Scale bars, 5 mm.
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Excessive IL-15 and the Genesis of Leukemiahas been shown to alter the risk of malignant transformation,
cytokines have only rarely been directly implicated as a cause
of cancer, and to date, mechanistic insights into this process
have not been understood.
IL-15 is a proinflammatory cytokine that is required for the
genesis and homeostasis of natural killer (NK) cells or large
granular lymphocytes (LGL) (Caligiuri, 2008). IL-15 utilizes the
b (CD122) and g (CD132) chains of the IL-2 receptor to transmit
its growth and activation signals in LGL, yet presents to the bg
receptor complex in trans via its binding to a high-affinity IL-15
receptor a chain (Dubois et al., 2002). IL-15 was first shown to
be overexpressed in HTLV-1-associated human T cell leukemia,
and interruption of its autocrine loop with an anti-CD122 mab
prevented leukemic cell growth and induced leukemic cell death
in vitro (Bamford et al., 1994;Grabstein et al., 1994) but not in vivo
(Morris et al., 2006). Overexpression of murine IL-15 causes LGL
leukemia with either a NK cell or TNK cell phenotype in IL-15
transgenic (Tg) mice (Fehniger et al., 2001), and mice overex-
pressing mutated HMGI-C express excessive IL-15 that causes
NK lymphoma (Baldassarre et al., 2001). Interestingly, IL-15 has
been reported to be overexpressed in human LGL leukemia and
to date, most human cell lines isolated from patients with LGL
leukemia are dependent on IL-2 or IL-15 for in vitro propagation
(Zambello et al., 1997). Collectively, these experimental and clin-
ical data suggest a central role for IL-15 in the genesis of LGL
leukemia, a highly malignant and uniformly fatal disorder, yet
the mechanism by which this cytokine induces malignant trans-
formation of LGL is not known. In this study, we attempt to
unravel the mechanism of IL-15-induced LGL leukemia in mouse
and man.
RESULTS
Chronic In Vitro Exposure of Normal LGLs to IL-15
Results in Leukemic Transformation
Because overexpression of IL-15 as a single growth factor can
initiate leukemic transformation of LGL in vivo (Fehniger et al.,
2001) and the neoplastic cells isolated from patients with LGL
leukemia have higher expression of IL-15 than their normal LGL
counterparts (Figure 1A), we first assessed the effects of IL-15
on wild-type (WT) mouse LGL (>95% CD3-NK1.1+) to determine
if this transformation could occur in vitro (Figure 1B). Culture of
1 3 105 WT LGL with IL-15 at a concentration sufficient to satu-
rate its cognate dimeric receptor induced robust growth of the
LGL, which has continued for over 18 months while maintaining
the LGLphenotype (Figures 1Cand1D). At 6months, a karyotype
was performed demonstrating striking aneuploidy (Figure 1E).
While withdrawal of IL-15 led to eventual apoptosis of LGL
in vitro (data not shown), adoptive transfer intoSCIDmicewithout
exogenous IL-15 resulted in a dramatic increase in white blood
cell (WBC) count (4.2 3 107/ml), splenomegaly, and death from
fatal leukemia in vivo (Figures 1B and 1F). Interphase fluores-
cence in situ hybridization (FISH) analysis of splenocytes from
the leukemic mouse revealed multiple copies of chromosome
15 (Figure 1F) as was seen in the in vitro culture before adoptive
transfer (Figure 1E), and in our original IL-15 Tg mice (Yokohama
et al., 2010). Thus, chronic exposure of WT LGL to IL-15 alone
contributes to robust growth and chromosomal instability (CIN)
in vitro, and leukemic transformation in vivo.646 Cancer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Inc.
Figure 2. IL-15 Induces Centrosome Aberration in Normal LGLs
(A) The size, structure, and number of human centrosomes was determined by
confocal microscopy and immunoflorescence staining with Pericentrin (green)
in both freshly isolated normal humanCD56+ or CD8+ LGL (top left) as well as in
malignant cells from three patients with acute LGL leukemia. Cells were
counterstained with DAPI (blue) for nuclear staining. Images shown are
representative of slides with 105 cells. Scale bars, 5 mm.
(B) The size, structure, and number of mouse centrosomes was determined by
confocal microscopy and immunoflorescence staining with GTU88 (green) in
both freshly isolatedWT LGL (top left) as well as inWT LGL cultured in IL-15 for
6 months (top middle and right). Cells were counterstained with DAPI (blue) for
nuclear staining. Images shown here are representative of three different slide
preparation with 105 cells. Graphical quantification of these centrosomal
abnormalities is shown immediately below as percentage of cells (mean ±
SEM) presenting centrosomal abnormalities from three independent slide
preparations. Scale bars, 5 mm.
(C) Relative fold changes (mean ± SEM) in mRNA expression of AurkA and
AurkB in splenocytes from LGL leukemic mice relative to values measured in
fresh WT LGL. Quantification was by Real-time RT-PCR (n = 3 each). Each
measurement was normalized against the level of 18SmRNA, and then values
for AurkA and AurkB in fresh WT LGL were arbitrarily set at 1.
(D) Relative fold changes (mean ± SEM) in mRNA expression of AurkA and
AurkB for WT LGL cultured in IL-15 for 30 days, relative again to values
measured in fresh WT LGL, which are arbitrarily set at 1 (n = 3 each).
(E) Relative fold changes (mean ± SEM) in mRNA expression of Myc in sple-
notyces from LGL leukemic mice (n = 3), and in WT mouse LGL cultured in
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CanIL-15 Induces Centrosome Aberrations in Normal LGL
One proposed mechanism underlying CIN is centrosome-medi-
ated asymmetric chromosome segregation resulting in aneu-
ploidy (Ganem et al., 2009). Indeed we found numerical and
structural centrosomal aberrations in primary cells obtained
from patients with aggressive LGL leukemia (Figure 2A). We
next assessed WT mouse LGL cultured for several months in
IL-15 for centrosome aberrancies and compared them to fresh
WT LGL. We found that the vast majority (81 of 97) of IL-15
cultured LGL counted had significant increases in centrosome
numbers and/or size, while no such changes were noted in
263 fresh WT LGL (Figure 2B). Since altered regulation of cen-
trosome replication can be caused by excessive aurora kinases
encoded by AurkA and AurkB (Giet et al., 2005), we assessed
the expression of these transcripts in LGL leukemic blasts from
IL-15 Tg leukemic mice and found each to be significantly
elevated in comparison to WT LGL from age-matched WT
mice, although AurkB was significantly higher than AurkA (Fig-
ure 2C). Similarly, WT LGL exposed to IL-15 for only 30 consec-
utive days also showed higher transcript levels of AurkA and
AurkB compared to the fresh LGL, although AurkA was signifi-
cantly higher than AurkB (Figure 2D). Interestingly, overexpres-
sion of AurkA can transform rodent fibroblasts while AurkB
cannot (Bischoff et al., 1998; Kanda et al., 2005; Zhou et al.,
1998). This may explain the relative abundance of AurkA earlier
in this process. Indeed, we show that forced overexpression of
AurkA in WTmouse LGL exposed to IL-15 in a short-term culture
resulted in quantitative and qualitative centrosome abnormalities
aswell as enhanced transformation in vitro (Figures S1A andS1B
available online).
Because AurkA and AurkB are regulated by Myc (den Hol-
lander et al., 2010), we measured and found increased tran-
script levels of Myc in both leukemic blasts as well as in the
WT LGL cultured with IL-15 for 12 hr and for 30 days, and
confirmed this at the protein level for both WT mouse and
normal human LGL (Figures 2E, S1C and, S1D). This eleva-
tion of AURKA, AURKB, and MYC expression was confirmed
in primary human LGL leukemia samples (Figure S1E). Chro-
matin immmuo-precipitation (ChIP) assays performed on WT
mouse LGL that had been cultured in IL-15 for 6 months and
then starved of IL-15 for 24 hr followed by re-stimulation with
IL-15 or PBS for 4 hr demonstrated an increased binding of
Myc within promoter regions of AurkA and AurkB (Figure 2F).
Specific reduction of Myc by shRNA in IL-15-activated WT
mouse LGL drastically reduced AurkA and AurkB expression
(not shown). These data suggest that IL-15-mediated induction
of Myc can lead to CIN in part via overexpression of AurkA and
AurkB.
Using a luciferase construct, we next demonstrated that
IL-15 induces Myc at least in part via activation of NF-kBp65IL-15 for 30 days. Both measurements are relative to values ofMycmeasured
in fresh WT LGL that are arbitrarily set at 1.
(F) WT LGLwere grown in vitro with IL-15 for approximately 6months, and then
harvested and starved for 24 hr and then divided up to be restimulated with
either IL-15 or PBS for 4 hr. ChIP assay was performed using an anti-Myc
antibody and PCR primers amplifying the AurkA and AurkB promoter 50
regulatory regions.
See also Figure S1.
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Figure 3. Aberrant DNA Methylation and
Methytransferase Activity Contribute to IL-
15-Induced LGL Leukemia
(A) Relative fold increase in GDM levels in sple-
nocytes from LGL leukemic mice (n = 4) and in
WT LGL cultured in IL-15 (n = 3) for 30 days rela-
tive to values of GDM measured in fresh WT LGL
(n = 4), which is arbitrarily set at 1. Quantification
was done by mass spectrophotometry and shown
as mean ± SEM.
(B) Relative fold changes in mRNA expression of
Dnmt3b, in splenocytes from LGL leukemic mice
(n = 3) and in WT LGL cultured in IL-15 (n = 3) for
30 days relative to values of Dnmt3b measured in
fresh WT LGL (n = 3). Quantification was by real-
time RT-PCR and shown as the mean ± SEM.
Each measurement was normalized against the
level of 18SmRNA, and then values of Dnmt3b for
fresh WT LGL were arbitrarily set at 1.
(C) Fold changes (mean ± SEM) in mRNA ex-
pression ofDNMT3B in three human LGL leukemia
patient (Pt) samples, relative to values of DNMT3B
measured in normal donors cells that were en-
riched for either CD56+ or CD8+ (n = 4 each) and
arbitrarily set at 1. Each sample was normalized to
18S mRNA.
(D) Confocal analysis of Dnmt3b protein expres-
sion in mouse and human LGL leukemia relative to
normal LGL. Assay was done by immuno-labeling
the cells with anti-Dnmt3b antibody. Data are
representative of at least four independent mice,
patients and normal donors. Cells were counter-
stained with DAPI (blue) for nuclear staining. Scale
bars, 10 mm.
(E) WBC counts of different genotypes of adult
mice generated from mating IL-15 Tg and
DNMT3B Tg parents. The horizontal bar in each
lane indicates the mean WBC count for 6-36 mice
per group. Also included are four representative
images from Wright-Giemsa staining of blood
smears for each of the four genotypes, and an
image of four whole spleens obtained frommice of
each genotype.
(F) Comparative survival of DNMT3B Tg and WT
mice (both 100%), IL-15 Tg, and IL-15/DNMT3B
Tg mice.
See also Figure S2.
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NF-kB binding sites within the Myc promoter after 1 hr and
12 hr of exposure to IL-15 in both mouse (Figure S1G, left)
and human LGL (Figure S1H, left). Supershift assay docu-
mented NF-kBp65 and p50 binding to the Myc promoter
following LGL cell stimulation by IL-15 for 12 hr in both mouse
(Figure S1G, right) and human LGL (Figure S1H, right). Finally,
utilizing a ChIP assay, we demonstrated an enrichment of NF-
kBp65 at the consensus binding site of the mouse Myc and
human MYC promoter following LGL cell stimulation by IL-15
for 4 hr (Figures S1I and S1J). Thus, IL-15-mediated induction
of Myc in normal LGL occurs, at least in part, via the activation
of NF-kB.648 Cancer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier IncIL-15 Increases Global DNA Methylation Levels in LGL
Hypermethylation of tumor suppressor and ‘‘stability’’ genes can
also contribute to CIN (Esteller, 2006; Esteller, 2007), so we also
pursued this in our mouse model. We previously showed that
leukemic blasts from IL-15 Tg mice have an increase in methyla-
tion within the 50 regulatory region of genes (Yu et al., 2005). We
confirmed an increase in global DNA methylation (GDM) within
LGL leukemic blasts from IL-15 Tg mice compared to age-
matched WT LGL controls. We also measured a GDM increase
in WT mouse LGL cultured with IL-15 for 30 days, suggesting
that IL-15 is inducingmethylation before leukemic transformation
(Figure 3A). A similar increase in GDM was seen in our primary
human LGL leukemia samples (Figure S2A). We investigated.
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for IL-15-mediated hypermethylation by measuring the mRNA
levels of Dnmt1, Dnmt3a, and Dnmt3b in LGL leukemic blasts
from IL-15 Tg mice and in WT LGL cultured with IL-15. Only
Dnmt3b (mRNA and protein) was consistently elevated in both
populations (Figure 3B and top row of Figure 3D). Further, only
the expression of DNMT3B was consistently elevated in primary
leukemic blasts from patients with LGL leukemia (Figure 3C and
bottom row of Figure 3D), and was abundant in the nucleus of
normal human LGL stimulated with IL-15 (Figure S2B). These
data suggest that IL-15 may mediate hypermethylation of DNA
in LGL at least in part via an induction of DNMT3B.
De Novo Overexpression of DNMT3B Augments the
Incidence of LGL Leukemia In Vivo
We created DNMT3B Tg mice driven by the Vav1 promoter (Fig-
ure S2C). In vitro, we demonstrated that LGL from these mice
show enhanced transformation in the presence of IL-15, when
compared to WT mouse LGL in the presence of IL-15 (Fig-
ure S2D). In contrast, mouse LGL with reduced expression of
Dnmt3b showed a decrease in transformation in the presence
of IL-15 when compared to WT mouse LGL in the same assay
(Figure S2E). DNMT3B Tg mice were found to have a normal
phenotype and life expectancy similar to their WT littermates
(not shown). Mating IL-15 Tg andDNMT3B Tg parents generated
four different genotypes: IL-15 Tg, DNMT3B Tg, IL-15/DNMT3B
Tg, and WT mice. IL-15/DNMT3B Tg mice showed an increase
in WBC count significantly earlier than their IL-15 Tg counter-
parts, while DNMT3B Tg mice and WT mice had normal WBC
counts (Figure3E). IL-15/DNMT3BTgmiceshowedasignificantly
shorter latency and 100% incidence of fatal LGL leukemia
comparedwith IL-15 Tgmice (Figures 3F and S2F). The immuno-
phenotype of IL-15/DNMT3B Tg leukemia was similar to that
of IL-15 Tg leukemia (Yokohama et al., 2010) (not shown) but
IL-15/DNMT3B Tg mice had lymphadenopathy (Figure S2G).
Thus, excess expression of DNMT3B does not initiate leukemia
but contributes to its progression upon chronic exposure with
IL-15.
Both the IL-15 Tg and the IL-15/DNMT3B Tg mice had signif-
icantly greater CpG methylation, as measured by LINE-1 hypo-
methylation (Este´cio et al., 2007; Ogino et al., 2008), when
compared to the DNMT3B Tg and WT mice (Figure S2H). While
the differences in these measurements as well as those seen in
Figure S2A appear modest, they measure methylation across
the entire genome, rather than methylation of specific tumor
suppressor genes.We previously documented promotermethyl-
ation and silencing of the tumor suppressor Idb4 in leukemia
from IL-15 Tg mice (Yu et al., 2005). Notably, Idb4 promoter
methylation was more pronounced in LGL leukemia from IL-
15/DNMT3B Tg mice compared to that of IL-15 Tg mice (Fig-
ure S2I). Culture of WT LGL with IL-15 for 30 days also resulted
in methylation of the Idb4 promoter, albeit not as striking as seen
in primary LGL leukemia samples from IL-15 Tgmice (Figure S2I).
In contrast, LGL from DNMT3B Tg mice did not show any meth-
ylation at the Idb4 promoter, similar toWT LGL (Figure S2I). Thus,
overexpression of DNMT3B without IL-15 overexpression was
insufficient to cause Idb4 promoter methylation. Collectively,
these results indicate that the overexpression of DNMT3B is
likely necessary but without overexpression of IL-15 is insuffi-Cancient for the hypermethylation of DNA noted in LGL chronically
exposed to this cytokine.
IL-15 Regulates Expression of DNMT3B via Repression
of MicroRNA (miR)-29b
We have reported that Dnmt3b is a direct, negatively regulated
target ofmiR-29b and repression ofmiR-29b is induced by bind-
ing of Myc, Hdac-1, and NF-kBp65 to its promoter (Chang et al.,
2008; Garzon et al., 2009b; Liu et al., 2010). We showed that
short-term culture of WT mouse LGL with IL-15 induces Myc
protein via NF-kB (Figures S1F–S1I). Similar data were obtained
for Myc and NF-kB for both long-term cultures ofWTmouse LGL
in IL-15 (Figure 4A) as well as in mouse and human LGL leukemia
(Figures 4B and 4C). Finally, we used a ChIP assay to show
increased binding of Myc, Hdac-1, and NF-kBp65 repressors
to themiR-29b 50 regulatory region inWTmouse LGL first starved
and then re-exposed to IL-15 (Figure 4D). Similar resultswere ob-
tained in splenocytes from LGL leukemia in IL-15 Tg mice when
compared to WT mouse splenocytes (Figure S3). As a result of
these experiments, we postulated that IL-15 stimulation of WT
LGL represses miR-29b via Myc, Hdac-1, and NF-kBp65.
Indeed, when compared to fresh WT LGL, miR-29b expres-
sion was significantly decreased in LGL leukemia from IL-15
Tg mice (p < 0.02) as well as in WT mouse LGL stimulated with
IL-15 for 12 hr (Figure 4E). We found similar striking results in
human LGL leukemia (p < 0.0009) and in normal human LGL
incubated with IL-15 (p < 0.003) (Figures 4F and 4G). Further,
forced overexpression of miR-29b by 40- to 60-fold in IL-15-
activated WT mouse LGL was associated with a proportional
decrease in Dnmt3b expression (Figures 5A and 5B), while the
reduction of Myc expression by shRNA in IL-15-activated WT
mouse LGL significantly increased miR-29b expression and
decreased Dnmt3b expression (not shown). Thus, the IL-15-
mediated induction of Myc, NF-kB, and Hdac-1 repressors in
WT mouse LGL results in a decrease in miR-29b expression
that in turn increases Dnmt3b expression.
To further confirm the role of miR-29b in IL-15-mediated LGL
leukemia, we overexpressed miR-29b in fresh WT LGL cells,
which were then cultured in IL-15 for 8–10 days prior to assess-
ment for early evidence of transformation in vitro. We noted that
overexpression ofmiR-29b was inversely associated with IL-15-
mediated LGL transformation compared to control transfected
cells, i.e.,WTLGLwithoverexpressionofmiR-29b showedsignif-
icantly less IL-15-mediated transformation (Figure 5C). Further-
more, a significant decrease of miR-29b expression in WT LGL
cells transfected with miR-29b antagomir and cultured in IL-15
for 8–10days resulted in a significant increase in their transforma-
tion compared with the same LGL transfected with a scrambled
control (Figures 5D and 5E). Thus, collectively, we provide evi-
dence in WT LGL for a mechanistic link between IL-15-mediated
downregulation of miR-29b, increased Dnmt3b, and enhanced
transformation in short-term cultures with IL-15, as well as in-
creased methylation of the genome, including the tumor sup-
pressor Idb4, in WT LGL cells chronically exposed to IL-15.
A Formulation of a Proteasomal Inhibitor Provides Long-
Term Disease-free Survival in Leukemic Mice
Because our previous data reveal that it is possible to re-
verse miR-29b repression in leukemia cells by targeting thecer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Inc. 649
Figure 4. Alteration of Gene Expression by
IL-15 and in LGL Leukemia
(A) Confocal analysis of fresh WT mouse LGL
and WT mouse LGL cultured in IL-15 for 30 days
was performed by immunolabeling the cells with
anti-Myc and anti-NF-kBp65 as above. Scale
bars, 5 mm.
(B) Confocal analysis of spleen samples from
LGL leukemic mice and fresh WT LGL for Myc and
NF-kB was performed by immuno-labeling of the
cells with the respective antibody. Cells were
counterstained with DAPI (blue) for nuclear stain-
ing. Data are representative of at least five inde-
pendent mice evaluated for protein expression.
Scale bars, 10 mm.
(C) Confocal analysis of enriched LGL from normal
human donor blood samples compared with LGL
leukemia samples from patients. Immuno-staining
was done by incubating the cells with anti-MYC
and an anti-NF-kBp65 antibody. Data are repre-
sentative of at least four independent normal
donors and LGL leukemia patients evaluated for
protein expression. Scale bars, 10 mm.
(D) In vitro culturedWT LGL were grown with IL-15
for approximately 8 months, then harvested and
starved for 24 hr and then divided up to be re-
stimulated with either IL-15 or PBS for 4 hr. A ChIP
assay was performed using the indicated anti-
body. The gel image shows the PCR product of
the indicated gene performed on ChIP DNA with
primers designed for amplification along the
miR-29b promoter/enhancer region. The data are
representative of three independent experiments.
(E) Fold decrease (mean ± SEM) in miR-29b tran-
script levels in splenocytes from LGL leukemic
mice (n = 4) and in WT LGL cultured in IL-15 (n = 4)
for 12 hr relative to value of miR-29b measured in
fresh WT LGL (n = 4) which is arbitrarily set at 1.
Each sample was normalized to U6.
(F) Fold changes (mean ± SEM) in expression of
miR-29b transcript levels in human LGL leukemia
samples, normalized to U6 and then quantified
relative to values of miR-29b measured in normal
donor cells that were enriched for either CD56+ or
CD8+ (n = 4 each) and then arbitrarily set at 1.
(G) Fold changes (mean ± SEM, n = 3) in expression ofmiR-29b in CD3-CD56+ normal human donor LGL from IL-15 stimulated and PBS treated control for 12 hr
relative to values of miR-29b measured in unstimulated normal donor LGL and arbitrarily set at 1. Each measurement was normalized against the level of U6.
See also Figure S3.
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pharmacologic proteasome inhibitors (Garzon et al., 2009b; Liu
et al., 2010), we exposed LGL leukemia blasts from IL-15 Tg
mice to the proteasome inhibitor bortezomib for 2 hr, and ob-
served a 13,000-fold upregulation of miR-29b when compared
to blasts treated with PBS (n = 3, p = .02; Figure 6A). This resur-
gence inmiR-29b expression within 2 hr of treatment is followed
by its return to levels seen in WT cells, suggestive of a block in
the binding of Myc, Hdac-1, and NF-kBp65 to the miR-29b
promoter. We also noted a significant (50-fold) decrease in
Dnmt3b transcript in bortezomib-treated LGL leukemic blasts
at 48 and 72 hr, compared to PBS-treated blasts (Figure 6B),
which was validated at the protein level (Figure 6C). Targeting
the transcriptional repressors ofmiR-29b also led to a significant
re-expression of the tumor suppressor gene Idb4 compared to
PBS-treated blasts (Figure 6D). COBRA analysis confirmed this650 Cancer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Incwas due to reduction in Idb4 promoter methylation (Figure 6E).
Notably, this in vitro treatment with bortezomib not only resulted
in downregulation of Dnmt3b, but also reduced expression of
AurkA and AurkB transcript in leukemic blasts compared to
PBS treated blasts (Figures S4A and S4B). Marked apoptosis
of WT LGL in the presence of IL-15 as well of LGL leukemia
was noted with the in vitro treatment with bortezomib, which
may also be secondary to the drug’s effect on the induction of
pro-apoptotic Bid, as previously reported (Hodge et al., 2009).
We reported that in vivo treatment of ICR-SCIDmice engrafted
with primary LGL leukemia from IL-15 Tg mice with a DNA
hypomethylating agent that targets Dnmt1 (i.e., decitabine) or
in combination with a HDAC inhibitor (i.e., depsipeptide) was
either ineffective or highly toxic, respectively (Yu et al., 2009).
To test the efficacy of bortezomib, we needed to first improve
the in vivo pharmacodynamics of the drug because the naked.
Figure 5. Mir-29b Overexpression or Repression Alters LGL Trans-
formation
(A) Relative fold overexpression (mean ± SEM) of miR-29b in WT mouse LGL
transfected with scrambled control or pre-miR-29b, relative to the value
measured in mock transfected LGL (not shown), which is arbitrarily set at 1.
Each sample was normalized to U6.
(B) Relative fold changes (mean ± SEM, n = 3) in mRNA expression of Dnmt3b
in LGL shown in (A). Each measurement was normalized against the level of
18S mRNA, and then values of Dnmt3b for mock transfected LGL cells were
arbitrarily set at 1.
(C) LGL similarly transfected with scrambled control or pre-miR-29b as shown
in (A) were then plated at 1 3 105/well in triplicate and cultured with IL-15 in
a semisolid agar medium for 8–10 days after which CFU are detected and
quantified in a cell transformation assay using a microtiter plate reader as
described in Experimental Procedures. Percent transformation of pre-miR-
29b transfected LGL relative to control (scrambled transfected LGL, arbitrarily
set at 100%) is shown as mean ± SEM, n = 3 each.
(D) In vitro culturedmouse LGLwere transfectedwith 50 pmole solution of LNA
control or LNAmiR-29b inhibitor oligonuleotide per manufacturer’s instruction
by electroporation. Cells were measured for miR-29b expression levels 24 hr
post transfection.
(E) WT mouse LGL were plated at 1x105/well in triplicate and cultured with IL-
15 in a semisolid agar medium for 8–10 days after which CFU are detected and
quantified in a cell transformation assay using a microtiter plate reader as
described in Experimental Procedures. Percent transformation of cells relative
to LNA control (arbitrarily set at 100%) is shown as mean ± SEM, n = 3 each.
Cancer Cell
Excessive IL-15 and the Genesis of Leukemiacompound was toxic and ineffective. We therefore developed
a liposomal preparation (Figure S4C). Four weeks after ICR-
SCID mice were engrafted with a lethal dose of LGL leukemic
blasts from IL-15 Tg mice, a twice-weekly treatment with the
liposomal bortezomib was initiated at the dose of 1.0 mg/kg/
mouse for the first week, which was continued at the dose ofCan2.0 mg/kg/mouse for next 2 weeks while monitoring for any
clinical signs of toxicity or leukemia-related distress. In a ran-
domized trial, control mice treated with a preparation of empty
liposomes first succumbed to fatal LGL leukemia within 60–
80 days following infusion of the LGL leukemic blasts, and
mice treated with free bortezomib at a similar dose and schedule
as liposomal bortezomib all died from leukemia generally within
the same time. However, the mice engrafted with LGL leukemia
and treated with liposomal bortezomib showed 100% survival
130 days following infusion of the LGL leukemic blasts, without
any evidence of toxicity (Figure 6F). Spleens from mice treated
with liposomal bortezomib were significantly reduced in weight
(Figure S4D) and histologic examination showed a clearance of
leukemic blasts from liver and spleen (not shown).
DISCUSSION
There are previous reports documenting the increased risk of
cancer in association with aberrant cytokine signaling, and a
few murine models where their overexpression of cytokines
(i.e., IL-9 or IL-15) induces malignant transformation (Fehniger
et al., 2001; Renauld et al., 1994; Waldmann and Tagaya,
1999), yet mechanistic data regarding the latter remains incom-
plete (Hodge et al., 2009; Yu et al., 2005). The crucial role of IL-15
in the survival and proliferation of LGL leukemia has also been
well documented in both humans and mice (Fehniger et al.,
2001; Yokohama et al., 2010; Zambello et al., 1997). Abnormal
expression of IL-15 has been described in patients with other
lymphoid malignancies and autoimmune diseases including
rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory
bowel disease, and also in diseases associated with human
T cell lymphotropic virus I (HTLV-I) (Asadullah et al., 2000; Azimi
et al., 1998, 1999; Carroll et al., 2008; D’Auria et al., 1999; Trentin
et al., 1997). Zambello et al. previously showed that membrane-
bound IL-15 is expressed on proliferating blast cells in LGL
leukemia patients (Zambello et al., 1997), and most if not all
human LGL leukemia cell lines require activation via the IL-
15Rbg for propagation in vitro, suggesting that IL-15 is required
for initiation and maintenance of leukemogenesis in vivo.
Here, we provide the evidence that IL-15 alone can immor-
talize WT LGL in vitro that, upon adoptive transfer in vivo,
undergoes fulminant leukemic transformation in the absence of
exogenous IL-15. This oncogenic effect is the result of two
distinct pathways by which IL-15 contributes to malignant trans-
formation: first via the induction of CIN and marked aneuploidy;
and second via an induction of DNA hypermethylation, which
can contribute both to CIN (Esteller, 2006, 2007; Ganem et al.,
2009) and to silencing of tumor suppressor genes (Figure 7).
We show that IL-15 inducesMyc, Hdac-1, and NF-kBp65, which
mediate downregulation of miR-29b and consequent overex-
pression of Dnmt3b, thereby hastening the onset of LGL leuke-
mia. Concurrent upregulation of IL-15, MYC, AURKA, AURKB,
NF-kBp65, and downregulation ofmiR-29 followed by upregula-
tion of DNMT3B and increased GDM, as well as centrosome
aberrancies were also demonstrated in primary patient LGL
leukemic blasts compared with normal controls.
There is currently no curative treatment for LGL leukemia and
the disease is fatal in most circumstances. Treatment options in-
clude methotrexate, cyclosporine A, or cyclophosphamide andcer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Inc. 651
Figure 6. In Vitro and In Vivo Targeting of
miR-29b Transcriptional Repression
(A) Fold increase inmiR-29b transcript at 1 (white)
and 2 (black) hr post in vitro bortezomib treatment
(20 mM). Both measurements normalized to U6
and then set relative to values of miR-29b mea-
sured in PBS treated LGL leukemia cells, which
are arbitrarily set at 1.
(B) Relative fold changes in mRNA expression
of Dnmt3b in bortezomib (20 nM) treated LGL
leukemia samples at 24, 48, and 72 hr, normalized
to 18SmRNA and then quantified relative to values
of Dnmt3b in PBS-treated LGL leukemia samples
that are arbitrarily set at 1. Data for (A) and (B) are
mean ± SEM (n = 3).
(C) Splenocytes from LGL leukemic mice were
treated in vitro with either control (PBS) or borte-
zomib (20 nM) for 24 hr and then immunoblotted
for Dnmt3b and actin that was used as an internal
control.
(D) Relative fold changes (mean ± SEM) in mRNA
expression of Idb4 in mouse LGL leukemia cells
treated in vitro with bortezomib (20 mM) at 24, 48,
and 72 hr, normalized to 18S mRNA, and then
quantified relative to values of Idb4 in PBS-treated
LGL leukemia samples that are arbitrarily set at 1.
(E) COBRA analysis for Idb4 promoter methylation
in splenocytes from LGL leukemic mice that were
treated in vitro for 72 hr with either control (PBS)
or bortezomib (20 nM). Amplification of the Idb4
promoter region and sequential COBRA analysis
with a methylation sensitive restriction enzyme
(BstU1) reveals only a partial loss of methylation at
the Idb4 promoter in LGL leukemia cells treated
with bortezomib (20 mM), but not PBS.
(F) Kaplan–Meier survival plot for ICR-SCID mice
(n = 6–8/group) after intravenous injection of
splenocytes from LGL leukemia mice. Disease-
free survival in mice treated with empty liposomes,
free bortezomib, and liposomal bortezomib.
See also Figure S4.
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Utecht and Kolesar, 2008), and are often associated with signif-
icant hematologic and other toxicities (Sokol and Loughran,
2006). Relatively little data exist on effective alternative therapies
for LGL leukemia. Targeting IL-15 or the b chain component of
its receptor as a means of immunotherapy has been suggested,
but has thus far not been successful in clinical trials for LGL
leukemia patients (Morris et al., 2006). Furthermore, our experi-
mental therapy with the Dnmt inhibitor decitabine targeting the
aberrant epigenetic changes observed in our preclinical model
of LGL leukemia resulted in only transient responses and associ-
ated hematologic toxicity, and the combination of decitabine
with a histone deacetylase inhibitor resulted in fatal toxicity (Yu
et al., 2009). These data therefore emphasize the need for
approaches aimed at the pathogenic mechanisms responsible
for initiation and maintenance of LGL leukemia. To pursue this
goal, we designed a therapeutic strategy that used liposomal
bortezomib to concurrently and effectively target upregulation
of Myc, activation of AurkA, AurkB, and NF-kBp65; and down-
regulation of miR-29, which were shown to play a pivotal role
in inducing CIN and aberrant Dnmt expression and in turn652 Cancer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Incleukemia. Garzon et al. have previously shown that decreased
miR-29b expression can also contribute to cancer progression
by a concomitant increased expression of the anti-apoptotic
Mcl-1 (Garzon et al., 2009a), and Hodge et al. have shown that
IL-15 can lower the pro-apoptotic Bid protein in LGL leukemia
via proteasome-mediated degradation (Hodge et al., 2009).
STAT3 also lies downstream of IL-15 receptor activation, and
LGL leukemia from our IL-15 Tg mice display constitutive activa-
tion if STAT3 (our data, not shown). The latter has been shown
to induce anti-apoptotic Mcl-1 expression in patients with LGL
leukemia (Epling-Burnette et al., 2001), and a recent study has
uncovered activating STAT3 mutations in a subset of patients
with chronic LGL leukemia (Johnston et al., 1995; Koskela
et al., 2012). Hence it is possible that some of the effects shown
to result from excessive IL-15 signaling in this report, as well
as other unknown effects, are mediated at least in part by an
activated STAT3. Extending and integrating these findings, ther-
apeutic strategies for IL-15-mediated cancers could be also
provided through the use of aurora kinase inhibitors, NF-kB
inhibitors, STAT3 inhibitors, and/or synthetic miRNAs that target
DNA methyltransferases (Chan et al., 2010)..
Figure 7. Schematic of the Proposed Network of IL-15-Mediated
Transformation of WT LGL to LGL Leukemia
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Excessive IL-15 and the Genesis of LeukemiaOur therapeutic effectively targets the proteasomal degrada-
tion pathway and transcriptional repressors/activators in vivo,
thereby inducing a long-term disease-free remission as a single
agent in this otherwise fatal and refractory malignancy. The
correlative data we provide from human LGL leukemia samples
document their overexpression of IL-15 as well as the two aber-
rant pathways that emanate from chronic stimulation by IL-15.
Collectively this offers a strong rationale for a therapeutic inter-
ventionwith liposomal bortezomib in patients with LGL leukemia.
EXPERIMENTAL PROCEDURES
Generation of Transgenic Mice
The Institutional Animal Care and Use Committee (IACUC) of The Ohio State
University (OSU) approved all procedures involving animals. Expression of
the humanDNMT3B in Tgmouse is driven by the Vav promoter, which restricts
expression to cells of hematopoietic lineage. The Vav-transgenic system is
well established for mouse models of hematopoietic disease (Ogilvy et al.,
1998). The transgenic construct, including a HA-tag, was injected into mouse
pronuclei and multiple offspring were obtained with variable numbers of the
transgene (Figure S2C) but with normal survival (Figure 3F). IL-15 Tg mice
were generated andmaintained as described previously (Fehniger et al., 2001).
In Vitro Culture of LGL Cells
To expand LGL cells in vitro, approximately 1 3 105 FACS sorted splenic
NK1.1+ cells were cultured in 96-well plates at a density of 1 3 105/100 ml
RPMI medium supplemented with b-mercaptoethanol, antibiotics, and
100 ng/ml of rhIL-15. Typically culture medium was refreshed every 48–
72 hr, and cells then transferred to six well plates and split back to original
density in culture when they reached a density of 1.6 3 106/100 ml.
Antibody Staining and Flow Cytometry
Spleen, bone marrow, and peripheral blood samples were harvested from
moribund mice following sacrifice and single cell suspensions were prepared
as described previously (Fehniger et al., 2001). The experiments were per-
formed according to the IACUC guidelines. The following fluorochrome-conju-
gated monoclonal antibodies (mAb) were purchased from BD PharMingen,
San Jose, CA and used for flow cytometry: anti-CD3 (clone 145-2C11), anti-
NK1.1 (clone PK136), anti-CD4 (clone RM4-5), and anti-CD8a (clone 53-6.7).
Human LGL enrichment antibodies, anti-CD56 (clone N901), and anti-CD3
(clone UCHT-1) were purchased from Beckman Coulter (Beckman Coulter,
Brea CA).
Enrichment of LGL
Normal human peripheral blood LGLs were enriched from leukopacks
purchased from the American Red Cross (Columbus, OH) to >70% cell purity
utilizing methods previously described (Park et al., 2009). Briefly, mononuclear
cells were obtained using Ficoll-Paque Plus (GE Healthcare, Little Chalfont,CanUnited Kingdom) and CD56+ cells were enriched using a Rosette separation
cocktail (StemCell Technologies, Vancouver, BC) following themanufacturer’s
instructions. Enriched LGLs were then sorted with BD FACSAria cell sorter
using anti-CD56 and anti-CD3. Sorted cells were >95% pure for CD56+CD3
population. Patient samples were obtained from the OSU Leukemia Tissue
Bank following informed consent. The OSU Institutional Review Board
approved all experiments performed with human materials.
Total RNA and DNA Isolation
Single cell suspension was spun down and the cell pellet was resuspended
in TRIzol Lysis reagent (Invitrogen, Carlsbad, CA) processed further using
miRNeasy Mini Kit and Reagents (QIAGEN, Valencia, CA). On-column DNA
digestion was performed to eliminate any residual DNA. Total RNA was eluted
using RNase-free water, and was quantified by NanoDrop 1000 Spectropho-
tometer (Thermo Scientific, Wilmington, DE). DNA isolations were performed
using QIAamp DNA Micro Kit (QIAGEN), according to manufacturer’s proto-
cols with the exception of the elution step, which was done with water instead
of Buffer AE.
First Strand Synthesis for RT-PCR and Quantitative Taqman PCR
cDNA was generated from approximately 100–500 ng of total RNA, using the
SuperScript First Strand Synthesis kit for RT-PCR (Invitrogen), according to
the manufacturer’s protocol. RT reaction was performed in a DNA Engine
Dyad Peltier Thermal Cycler (Bio Rad, Hercules, CA) using the following
program: 25C for 10 min (min), 42C for 50 min, and 70C for 10 min. For first
strand synthesis of miR-29b and U6, approximately 100 ng of RNA was pro-
cessed using the Applied Biosystems mir-RT kit (Applied Biosystems, Austin,
TX). Total RNA was added to a mix of dNTP mix, RT enzyme, 103 RT buffer,
RNase inhibitor, and each desired Taqman 53RT primer. RT reaction was per-
formed using the following temperature conditions: 16C for 30 min, 42C for
45min, and 85C for 5min and stored at 4C until needed for quantitative PCR.
Quantitative RT-PCR was performed using either 1ml of cDNA or its dilutions.
Briefly, 1 ml of sample was added to a 20 ml total reaction volume containing
203 RT Taqman Assay for desired gene or miRs, 23 Taqman Universal Fast
PCR Master Mix (Applied Biosystems). Reaction was performed in 96 well
Fast Optic Plates, and run using the 7900HT Fast Real-Time PCR System
(Applied Biosystems). Taqman probe ID for the genes can be provided upon
request.
Chromatin Immunoprecipitation Assays and Quantitative ChIP PCR
formiR-29b and the AurkA and AurkB Promoters
Approximately 2 3 107 cells were harvested from leukemic and WT mice and
the chromatin immunoprecipitation (ChIP) assay were performed as described
previously (Liu et al., 2010). For IL-15 stimulation experiments, WT LGL
cultured with IL-15 were first starved of IL-15 for 24 hr, washed twice with
cold RPMI medium, and then re-exposed to either PBS or IL-15 for 4 hr. The
following antibodies were purchased from AbCam (Cambridge, England)
and used for ChIP: anti-HDAC-1 (Ab7028) and anti-NF-kB p65 (Ab7970).
Anti-c-Myc antibody was purchased from Santa Cruz Biotechnology. ChIP
PCR was performed using Power SYBR PCR mix (Applied Biosystems) or
AmpliTaq Gold 360 PCR Master Mix using ChIP DNA, which was added to
25 ml total reaction volume containing 23 PCR mix, and 10 mM of miR-29b
forward and reverse primers (Sigma-Aldrich, St. Louis, MO). Primer sequence
can be provided upon request. Fold change in binding was compared using
input DNA as control. PCR for AurkA and AurkB was performed as described
previously (den Hollander et al., 2010).
Immunofluorescence Staining and Confocal Microscopy
Approximately 1–23 105 freshly harvested cells were spun onto a microscope
slide using Shandon Cytospin 4 cytofuge (Thermo Fisher Scientific, Waltham,
MA). The slides were fixed immediately with ice-cold acetone for 10 min and
washed twice with PBS and 20% FBS. Blocking was performed by incubating
the cells in protein-free blocking solution (Dako Denmark A/S, Glostrup,
Denmark) for 30 min. Cells were then stained with a 1:100 dilution of goat poly-
clonal to rabbit IgG anti-c-Myc, anti-Dnmt3b (Santa Cruz Biotechnology,
Santa Cruz, CA), or anti-NF-kBp65 (AbCam) at room temperature for 60 min.
Slides were washed twice with PBS containing 20% FBS before incubating
the cells with 1:40 dilution of Texas Red-X goat anti-rabbit IgG (Invitrogen,cer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier Inc. 653
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with PBS containing 20% FBS and mounted with VECTASHIELD Mounting
Medium with DAPI. Pericentrin (Abcam) and GTU-88 (Vector Laboratories,
Burlingame, CA) antibodies were used to perform centrosomal staining in
acetone fixed cells. Briefly, cells weremounted on Poly-L-Lysine coated slides
and fixed in ice-cold acetone for 5 min. Cells were incubated with either Peri-
centrin (for human samples) or GTU88 (for mouse samples) antibody for 1 hr at
room temperature followed by incubation with secondary antibody. Images
were acquired using Olympus FV1000-Filter Confocal microscope (Olympus,
Center Valley, PA) and analyzed with Olympus Fluoview software (version 2.0).
In Vitro Drug Studies
Cells were harvested from the spleens of leukemic mice. Cells were cultured in
RPMI 1640 containing 10% FBS, at 37C with 5% CO2 and 100 units/ml of
rhIL-2. Leukemic cells were incubated with 20 nM bortezomib or PBS for an
incubation time that varied with the experiment performed. Viable cells were
measured by trypan blue exclusion. Cells were harvested and washed with
PBS prior to DNA and RNA isolation.
Bisulphite Conversion and COBRA Analysis of Idb4 Promoter
Bisulphite conversion and COBRA Analysis of Idb4 promoter was performed
as described (Yu et al., 2005).
Transfection of Primary Murine LGL Cells
Transfections were performed using murine Dnmt3b and AurkA SureSilencing
shRNA plasmids purchased from SABiosciences’ (QIAGEN, Valencia, CA).
Overexpression plasmids were purchased from Origene (Origene, Rockville,
MD). Single cell suspension of LGL cells were transfected using the Amaxa
Nucleofection system (Lonza Cologne GmbH, Cologne, Germany). Briefly,
approximately 53 106 cells were transfected according to the manufacturer’s
protocol for AmaxaMouseMacrophageNucleofector Kit. Cells were assessed
for the expression of GFP 12–24 hr after transfection.
In Vitro Transformation Assay
Normal activated T cells can formmicroscopically visible colonies in semisolid
medium as early as 4–6 days following exposure to the transforming T cell
leukemia virus, HTLV1. These lymphocytes proved to be transformed in that
their proliferation subsequently became independent of growth factor. In the
absence of infection by HTLV1, normal activated T cells do not transform
and do not form colonies in semisolid medium (Aboud et al., 1987). We used
a slightly modified colony forming unit (CFU) assay to assess for transforma-
tion of WT mouse LGL exposed to IL-15 and forced overexpression of AurkA
or Dnmt3b or underexpression of miR-29b.
WT NK1.1+CD3- LGL were activated and expanded in vitro with IL-15 and
transfected by electroporation with 5 mg of GFP-plasmid DNA control
construct or a GFP-experimental vector construct as indicated in the figure
legends. Twenty-four hr after transfection, cells were sorted for GFP expres-
sion (95% purity) and seeded at the density of 0.5 3 105–1 3 105 cells/well
in 96 well plates in a semisolid agar medium without or with a supplement of
IL-15 (100 ng/ml). The semisolid agar colony formation assay was performed
per manufacturer’s instruction using the Cytoselect 96-Well Cell Transforma-
tion Assay Kit (Cell Biolabs Inc, San Diego, CA). Briefly, following an 8–10 day
incubation period, cell colonies are solubilized, lysed, detected, and quantified
by the provided MTT solution (Invitrogen, Carlsbad CA) in a microtiter plate
reader.
CFUs was absent from wells seeded with WT mouse LGL transfected with
the GFP-plasmid DNA control construct but without IL-15. CFUs quantified
in wells seeded with IL-15 and WT mouse LGL transfected with the GFP-
plasmid DNA control construct were labeled the control group and arbitrarily
assigned a transformation score of 100%. CFU quantified in wells seeded
with IL-15 and WT mouse LGL transfected with GFP plus the experimental
vector construct were labeled the experimental group and were scored as
a percent transformation relative to the control group.
In Vivo Drug Studies
Age and sex matched ICR-SCID mice were used to study in vivo transplant-
ability of the leukemia cells. Approximately 2 3 106 splenocytes obtained
from IL-15 Tg leukemic mice were intravenously injected into recipient mice.654 Cancer Cell 22, 645–655, November 13, 2012 ª2012 Elsevier IncUpon engraftment of leukemia (measured by increased peripheral WBC
count), mice were given two doses of either bortezomib or liposomal bortezo-
mib at the concentration of 1.0 mg/week/kg of body weight, followed by two
doses of 2.0 mg/week/kg of body weight for next 2 weeks. Empty liposomes
were injected as control. All the experimental mice were given drug or placebo
via tail vein injection for 3 consecutive weeks.
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